Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...